"目录号: HY-13943
CNX-774是口服活性的高效Btk抑制剂，IC50< 1 nM，能与活性位点上的Cys-481形成配体导向的共价键。
相关产品
PCI-32765-Acalabrutinib-GDC-0853-AVL-292-BMX-IN-1-GDC-0834-ONO-4059-LFM-A13-Evobrutinib-RN486-BGB-3111-CGI-1746-PCI 29732-QL47-Btk inhibitor 1-
生物活性
Description
CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.IC50 Value: <1 nM [1]Target: Btk KinaseIn biochemical assays, CNX-774 has demonstrated potent inhibition of Btk with an IC50 of <1nM in a continuous-read assay. The covalent bonding of CNX-774 to Btk was confirmed by incubating recombinant Btk protein with a 10-fold molar excess of CNX-774 for 1 hour at room temperature and analysis by MALDI-TOF MS. A shift of protein mass corresponding to the molecular weight of CNX-774 confirmed the covalent bonding of CNX-774 to Btk. Digestion of the covalently bonded Btk with pepsin followed by MSMS analysis established the bonding of CNX-774 to Cys-481. Cellular potency as well as prolonged duration of action of CNX-774 was demonstrated in Ramos cells by using a biotinylated covalent probe that targets the same Cysteine residue as CNX-774.CNX-774 was found to be >90% extractable after 2 hrs of incubation in both rat and human whole blood. These results demonstrate that CNX-774 has potent inhibitory activity towards the intended target, Btk, while achieving remarkable specificity in a variety of assays designed to assess off-target reactivity towards abundant cellular thiols and blood proteins.
References
[2].In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton's Tyrosine Kinase
